Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH). Materials and Methods A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib. Results The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO– group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients. Conclusion Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.
Abstract
Purpose We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH). Materials and Methods A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib. Results The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO– group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients. Conclusion Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.
참고문헌 (26)
- Allen CE, "Langerhans-cell histiocytosis", N Engl J Med, 379, pp.856~868 (2018)
- Tran G, "Langerhans cell histiocytosis : a neoplastic disorder driven by Ras-ERK pathway mutations", J Am Acad Dermatol, 78, pp.579~590 (2018)
- Heritier S, "Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis", JAMA Oncol, 1, pp.836~838 (2015)
- Heritier S, "BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy", J Clin Oncol, 34, pp.3023~3030 (2016)
- Badalian-Very G, "Recurrent BRAF mutations in Langerhans cell histiocytosis", Blood, 116, pp.1919~1923 (2010)
- Abla O, "Treatment of Langerhans cell histiocytosis : role of BRAF", MAPK inhibition, 2015, pp.2015, 565~570
- Cebollero A, "Comparative safety of BRAF and MEK inhibitors(vemurafenib, dabrafenib and trametinib)in first-line therapy for BRAFmutated metastatic melanoma", Mol Clin Oncol, 5, pp.458~462 (2016)
- Chapman PB, "Improved survival with vemurafenib in melanoma with BRAF V600E mutation", N Engl J Med, 364, pp.2507~2516 (2011)
- Hauschild A, "Dabrafenib in BRAF-mutated metastatic melanoma : a multicentre, open-label, phase 3 randomised controlled trial", Lancet, 380, pp.358~365 (2012)
- Hertzman Johansson C, "BRAF inhibitors in cancer therapy", Pharmacol Ther, 142, pp.176~182 (2014)
- Kieran MW, "A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors", Clin Cancer Res, 25, pp.7294~7302 (2019)
- Toll SA, "Sustained response of three pediatric BRAF(V600E)mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy", Oncotarget, 10, pp.551~557 (2019)
- Wang D, "Clinical research of pulmonary Langerhans cell histiocytosis in children", Chin Med J(Engl), 131, pp.1793~1798 (2018)
- "LCH evaluation and treatment guidelines" (2009)[URL]
- "Common Terminology Criteria for Adverse Events (CTCAE)" (2017)[URL]
- Henter JI, "HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis", Pediatr Blood Cancer, 48, pp.124~131 (2007)
- Ozer E, "BRAF V600E mutation : a significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis", Pediatr Dev Pathol, 22, pp.449~455 (2019)
- Heritier S, "Circulating cell-free BRAF(V600E)as a biomarker in children with Langerhans cell histiocytosis", Br J Haematol, 178, pp.457~467 (2017)
- Schadendorf D, "Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E)or BRAF(V600K)mutations treated with adjuvant dabrafenib plus trametinib(COMBI-AD) : a randomised, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.701~710 (2019)
- Awada G, "Longterm disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition", Blood Adv, 2, pp.2156~2158 (2018)
- Mourah S, "Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib", Blood, 126, pp.2649~2652 (2015)
- Hyman DM, "Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations", N Engl J Med, 373, pp.726~736 (2015)
- McClain KL, "CNS Langerhans cell histiocytosis : common hematopoietic origin for LCH-associated neurodegeneration and mass lesions", Cancer, 124, pp.2607~2620 (2018)
- Robert C, "Improved overall survival in melanoma with combined dabrafenib and trametinib", N Engl J Med, 372, pp.30~39 (2015)
- Yamazaki N, "Phase 1", 2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma, 2018, pp.45, 397~407
- Davies MA, "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases(COMBI-MB) : a multicentre, multicohort, open-label, phase 2 trial", Lancet Oncol, 18, pp.863~873 (2017)